Adverum Biotechnologies, Inc. (ADVM)
4.36
0.00 (0.00%)
USD |
NASDAQ |
Sep 08, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 95.92M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 23.16% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -- |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 99.20% |
Profile
| Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA. |
| URL | http://www.adverum.com |
| Investor Relations URL | https://investors.adverum.com |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Value |
| Next Earnings Release | N/A |
| Last Earnings Release | Mar. 31, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA. |
| URL | http://www.adverum.com |
| Investor Relations URL | https://investors.adverum.com |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Value |
| Next Earnings Release | N/A |
| Last Earnings Release | Mar. 31, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |